摘要
脯氨酸脱氢酶/脯氨酸氧化酶(PRODH / POX)是一种催化脯氨酸第一步降解的酶,过程中产生ROS和ATP。POX广泛分布于生物体中,并负责一些调节过程,如氧化还原稳态,渗透调节,细胞信号和氧化应激。最近数据表明,POX在肿瘤发生和肿瘤生长中起着重要的作用。POX可通过内在和外在的方式诱导细胞凋亡。由于ROS的产生,POX可诱导caspase-9活性,其可介导线粒体凋亡(内源性凋亡途径)。POX也能刺激TRAIL(肿瘤坏死因子相关凋亡诱导配体)和DR5(死亡受体5)的表达,导致procaspase-8裂解和外源性凋亡。然而,这种抑癌基因在一定环境条件下可作为一种促生存因子,但遗传毒性,炎症和代谢应激可能使POX从抑制肿瘤生长转为促进肿瘤生长。本文将讨论可以调节切换POX模式的潜在机制。
关键词: 细胞凋亡,癌,脯氨酸脱氢酶(PRODH),脯氨酸氧化酶(POX)。
图形摘要
Current Drug Targets
Title:Proline Oxidase (POX) as A Target for Cancer Therapy
Volume: 16 Issue: 13
Author(s): Joanna Kononczuk, Urszula Czyzewska, Joanna Moczydlowska, Arkadiusz Surażyński, Jerzy Palka and Wojciech Miltyk
Affiliation:
关键词: 细胞凋亡,癌,脯氨酸脱氢酶(PRODH),脯氨酸氧化酶(POX)。
摘要: Proline dehydrogenase/proline oxidase (PRODH/POX) is an enzyme catalyzing the first step of proline degradation, during which ROS and/or ATP is generated. POX is widely distributed in living organisms and is responsible for a number of regulatory processes such as redox homeostasis, osmotic adaptation, cell signaling and oxidative stress. Recent data provided evidence that POX plays an important role in carcinogenesis and tumor growth. POX may induce apoptosis in both intrinsic and extrinsic way. Due to ROS generation, POX may induce caspase-9 activity, which mediates mitochondrial apoptosis (intrinsic apoptosis pathway). POX can also stimulate TRAIL (tumor necrosis factorrelated apoptosis inducing ligand) and DR5 (death receptor 5) expression, resulting in cleavage of procaspase-8 and thus extrinsic apoptotic pathway. However, this tumor suppressor in certain environmental conditions may act as a prosurvival factor. Genotoxic, inflammatory and metabolic stress may switch POX from tumor growth inhibiting to tumor growth supporting factor. The potential mechanisms which may regulate switching of POX mode are discussed in this review.
Export Options
About this article
Cite this article as:
Joanna Kononczuk, Urszula Czyzewska, Joanna Moczydlowska, Arkadiusz Surażyński, Jerzy Palka and Wojciech Miltyk , Proline Oxidase (POX) as A Target for Cancer Therapy, Current Drug Targets 2015; 16 (13) . https://dx.doi.org/10.2174/138945011613151031150637
DOI https://dx.doi.org/10.2174/138945011613151031150637 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Determinants of Gastrointestinal and Liver Cancers: Role of Bile Acid Activated Nuclear Receptors
Current Topics in Medicinal Chemistry Therapeutic Nanosystems for Oral Administration of Insulin
Current Pharmaceutical Biotechnology Absorption, Disposition and Pharmacokinetics of Solid Lipid Nanoparticles
Current Drug Metabolism Diagnostic Performance of Magnetic Resonance Cholangiopancreatography (MRCP) for Biliopancreatic Cancer
Current Medical Imaging Rational Design of Non-Hydroxamate Histone Deacetylase Inhibitors
Mini-Reviews in Medicinal Chemistry Recent Advances in the Function of the 67 kDa Laminin Receptor and its Targeting for Personalized Therapy in Cancer
Current Pharmaceutical Design Heparin - a Key Drug in the Treatment of the Circulatory Degenerative Diseases: Controlling its Action with Polymers
Current Pharmaceutical Design The Role of Anionic Polysaccharides in the Preparation of Nanomedicines with Anticancer Applications
Current Pharmaceutical Design The Fabrication and Application of Bio-Functional Microspheres
Current Organic Chemistry Natural and Synthetic Agents Targeting Inflammation and Angiogenesis for Chemoprevention of Prostate Cancer
Current Cancer Drug Targets Serine Protease Inhibitor Kazal Type 1 (SPINK1): Beyond the Trypsin Inhibitor
Current Enzyme Inhibition Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
Current Pharmaceutical Design Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond
Current Pharmaceutical Design Phytosterols in Cancer: From Molecular Mechanisms to Preventive and Therapeutic Potentials
Current Medicinal Chemistry Molecular Targets in Gastrointestinal Stromal Tumors (GIST) Therapy
Current Cancer Drug Targets Interactions Between Plasma Proteins and Naturally Occurring Polyphenols
Current Drug Metabolism Trypanosomatid Enzymes as Targets for Plant-Derived Compounds: New Perspectives for Phytotherapeutic Approaches
Current Enzyme Inhibition Circulating Levels of Soluble Angiogenic Factors in Multiple Myeloma: Correlation with Parameters of Disease Activity and Prognosis
Current Angiogenesis (Discontinued) New Agents – Manifold Consequences: The Management of Lung and Colorectal Cancer is Changing
Current Cancer Therapy Reviews The Endocrine Regulation of Stem Cells: Physiological Importance and Pharmacological Potentials for Cell-Based Therapy
Current Stem Cell Research & Therapy